APA (7th ed.) Citation

Hirsch, F., Govindan, R., Zvirbule, Z., Braiteh, F., Rittmeyer, A., Belda Iniesta, C., . . . Gandara, D. (2014). Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC): Metastatic Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics, 90(5), S37. https://doi.org/10.1016/j.ijrobp.2014.08.215

Chicago Style (17th ed.) Citation

Hirsch, F.R, et al. "Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC): Metastatic Non-Small Cell Lung Cancer." International Journal of Radiation Oncology, Biology, Physics 90, no. 5 (2014): S37. https://doi.org/10.1016/j.ijrobp.2014.08.215.

MLA (9th ed.) Citation

Hirsch, F.R, et al. "Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC): Metastatic Non-Small Cell Lung Cancer." International Journal of Radiation Oncology, Biology, Physics, vol. 90, no. 5, 2014, p. S37, https://doi.org/10.1016/j.ijrobp.2014.08.215.